查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2132527

血紅素疾病市場規模、佔有率和趨勢分析報告：按疾病、類型（診斷、治療等）、地區和細分市場分類，預測期為 2026 年至 2033 年

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Disease Type (Thalassemia, Sickle Cell Disease), By Type (Diagnosis, Therapeutics, (Thalassemia, Sickle Cell Disease)), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血紅蛋白疾病市場概述

全球血紅素疾病市場預計到 2025 年將達到 110 億美元，從 2026 年的 119 億美元成長到 2033 年的 224 億美元，2026 年至 2033 年的複合年成長率為 9.4%。

北美市場主導，到 2025 年將佔銷售額的 39.9%。市場成長歸因於遺傳性血液疾病（特別是鐮狀細胞貧血症和地中海貧血）在非洲、中東、南亞和南美洲部分地區的負擔日益加重。

公眾意識的提高、新生兒篩檢計畫的擴展以及基因檢測的廣泛應用，正在加速疾病的早期診斷和管理。血紅素疾病產業涵蓋疾病修正治療、支持性治療、輸血製品、鐵螯合療法、基因療法以及用於篩檢和病患監測的診斷解決方案。監管機構對新療法的支持以及對基因醫學的持續投入，正在擴大可用的治療選擇。醫療衛生系統也增加專科血液疾病中心和罕見疾病計畫的數量，以改善患者照護。然而，高昂的治療費用、基礎設施不足以及缺乏專科醫療服務，仍限制許多中低收入國家獲得治療的機會。這些因素持續影響著區域醫療衛生市場的療法推廣、研究活動和商業機會。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：血紅素疾病市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：血紅素疾病市場：依疾病類型分類的商業分析

  • 按疾病類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按疾病類型分類，2021-2033 年
  • 地中海型貧血
  • 鐮狀細胞貧血症
  • 其他血紅蛋白（Hb）變體

第5章：血紅素疾病市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 診斷
  • 治療

第6章：血紅素疾病市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第7章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Vertex Pharmaceuticals Incorporated
    • Genetix Biotherapeutics Inc.
    • Novartis AG
    • Emmaus Life Sciences, Inc.
    • Bristol Myers Squibb
    • Novo Nordisk A/S
    • Beam Therapeutics Inc.
    • Editas Medicine, Inc.
    • Fulcrum Therapeutics, Inc.
    • Thermo Fisher Scientific Inc.
    • Sebia Group
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Siemens Healthineers AG
Product Code: 978-1-68038-736-0

Hemoglobinopathies Market Summary

The global hemoglobinopathies market size was valued at USD 11.0 billion in 2025 and is projected to grow from USD 11.9 billion in 2026 to USD 22.4 billion by 2033, at a CAGR of 9.4% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 39.9% in 2025. The market growth is driven by the growing burden of inherited blood disorders, particularly sickle cell disease and thalassemia, across Africa, the Middle East, South Asia, and parts of the Americas.

Growing awareness, expansion of newborn screening programs, and wider use of genetic testing are supporting earlier diagnosis and disease management. The hemoglobinopathies industry includes disease-modifying therapies, supportive treatments, blood transfusion products, iron chelation therapies, gene-based therapies, and diagnostic solutions used for screening and patient monitoring. Regulatory support for new therapies and continued investment in genetic medicine are expanding available treatment options. Healthcare systems are also increasing the number of specialized hematology centers and rare disease programs to improve long-term patient care. However, access to treatment remains limited in many low- and middle-income countries due to therapy costs, infrastructure gaps, and shortages of specialized healthcare services. These factors continue to shape treatment adoption, research activities, and business opportunities across regional healthcare markets.

Global Hemoglobinopathies Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemoglobinopathies market report based on disease type, type, and region:

  • Disease Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Thalassemia
  • Sickle Cell Disease
  • Other Hemoglobin (Hb) Variants
  • Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Diagnosis
    • Thalassemia
    • Blood test
    • Genetic test
    • Prenatal genetic testing
    • Pre-implantation genetic diagnosis
    • Hb Electrophoresis
    • Others
    • Sickle cell disease
    • Blood Test
    • Genetic Test
    • Prenatal Genetic Test
    • Electrophoresis
    • Others
    • Other Hemoglobin (Hb) Variants
    • Blood Test
    • Genetic Test
    • Prenatal Genetic Test
    • Electrophoresis
    • Others
  • Therapeutics
    • Thalassemia
    • Blood Transfusion
    • Iron Chelation Therapy
    • Bone Marrow Transplant
    • Others
    • Sickle Cell Disease
    • Blood Transfusion
    • Hydroxyurea
    • Bone Marrow Transplant
    • Others
    • Other Hemoglobin (Hb) Variants
    • Blood Transfusion
    • Hydroxyurea
    • Iron Chelation Therapy
    • Bone Marrow Transplant
    • Others
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Type
    • 1.2.2. Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hemoglobinopathies Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Hemoglobinopathies Market: Disease Type Business Analysis

  • 4.1. Disease Type Market Share, 2025 & 2033
  • 4.2. Disease Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million/Billion)
  • 4.4. Thalassemia
    • 4.4.1. Thalassemia Market, 2021 - 2033 (USD Million/Billion)
  • 4.5. Sickle Cell Disease
    • 4.5.1. Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
  • 4.6. Other Hemoglobin (Hb) Variants
    • 4.6.1. Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Hemoglobinopathies Market: Type Business Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
  • 5.4. Diagnosis
    • 5.4.1. Diagnosis Market, 2021 - 2033 (USD Million/Billion)
    • 5.4.2. Thalassemia
      • 5.4.2.1. Thalassemia Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.2. Blood Test
        • 5.4.2.2.1. Blood Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.3. Genetic test
        • 5.4.2.3.1. Genetic Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.4. Prenatal Genetic Testing
        • 5.4.2.4.1. Prenatal Genetic Testing Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.5. Pre-Implantation Genetic Diagnosis
        • 5.4.2.5.1. Pre-Implantation Genetic Diagnosis Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.6. Hb Electrophoresis
        • 5.4.2.6.1. Hb Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.2.7. Others
        • 5.4.2.7.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 5.4.3. Sickle Cell Disease
      • 5.4.3.1. Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.3.2. Blood Test
        • 5.4.3.2.1. Blood Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.3.3. Genetic Test
        • 5.4.3.3.1. Genetic Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.3.4. Prenatal Genetic Test
        • 5.4.3.4.1. Prenatal Genetic Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.3.5. Electrophoresis
        • 5.4.3.5.1. Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.3.6. Others
        • 5.4.3.6.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 5.4.4. Other Hemoglobin (Hb) Variants
      • 5.4.4.1. Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.4.2. Blood Test
        • 5.4.4.2.1. Blood Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.4.3. Genetic Test
        • 5.4.4.3.1. Genetic Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.4.4. Prenatal Genetic Test
        • 5.4.4.4.1. Prenatal Genetic Test Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.4.5. Electrophoresis
        • 5.4.4.5.1. Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
      • 5.4.4.6. Others
        • 5.4.4.6.1. Others Market, 2021 - 2033 (USD Million/Billion)
  • 5.5. Therapeutics
    • 5.5.1. Therapeutics Market, 2021 - 2033 (USD Million/Billion)
    • 5.5.2. Thalassemia
      • 5.5.2.1. Thalassemia Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.2.2. Blood Transfusion
        • 5.5.2.2.1. Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.2.3. Iron Chelation Therapy
        • 5.5.2.3.1. Iron Chelation Therapy Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.2.4. Bone Marrow Transplant
        • 5.5.2.4.1. Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.2.5. Others
        • 5.5.2.5.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 5.5.3. Sickle Cell Disease
      • 5.5.3.1. Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.3.2. Blood Transfusion
        • 5.5.3.2.1. Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.3.3. Hydroxyurea
        • 5.5.3.3.1. Hydroxyurea Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.3.4. Bone Marrow Transplant
        • 5.5.3.4.1. Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.3.5. Others
        • 5.5.3.5.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 5.5.4. Other Hemoglobin (Hb) Variants
      • 5.5.4.1. Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.4.2. Blood Transfusion
        • 5.5.4.2.1. Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.4.3. Hydroxyurea
        • 5.5.4.3.1. Hydroxyurea Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.4.4. Iron Chelation Therapy
        • 5.5.4.4.1. Iron Chelation Therapy Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.4.5. Bone Marrow Transplant
        • 5.5.4.5.1. Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
      • 5.5.4.6. Others
        • 5.5.4.6.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Hemoglobinopathies Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Hemoglobinopathies Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million/Billion)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.5. Europe
    • 6.5.1. Europe Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.7. Latin America
    • 6.7.1. Latin America Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Hemoglobinopathies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Vertex Pharmaceuticals Incorporated
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Genetix Biotherapeutics Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Emmaus Life Sciences, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bristol Myers Squibb
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novo Nordisk A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Beam Therapeutics Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Editas Medicine, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Fulcrum Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Thermo Fisher Scientific Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Sebia Group
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. F. Hoffmann-La Roche Ltd.
      • 7.5.12.1. Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Abbott Laboratories
      • 7.5.13.1. Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives
    • 7.5.14. Siemens Healthineers AG
      • 7.5.14.1. Overview
      • 7.5.14.2. Financial Performance
      • 7.5.14.3. Product Benchmarking
      • 7.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Hemoglobinopathies Market, by region, 2021 - 2033 (USD Million/Billion)
  • Table 4 Global Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 5 Global Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 6 North America Hemoglobinopathies Market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 7 North America Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 8 North America Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 9 U.S. Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 10 U.S. Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 11 Canada Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 12 Canada Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 13 Mexico Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 14 Mexico Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 15 Europe Hemoglobinopathies Market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 16 Europe Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 17 Europe Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 18 UK Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 19 UK Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 20 Germany Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 21 Germany Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 22 France Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 23 France Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 24 Italy Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 25 Italy Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 26 Spain Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 27 Spain Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 28 Norway Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 29 Norway Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 30 Denmark Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 31 Denmark Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 32 Sweden Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 33 Sweden Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 34 Asia Pacific Hemoglobinopathies Market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 35 Asia Pacific Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 36 Asia Pacific Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 37 Japan Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 38 Japan Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 39 China Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 40 China Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 41 India Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 42 India Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 43 Australia Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 44 Australia Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 45 South Korea Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 46 South Korea Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 47 Thailand Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 48 Thailand Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 49 Latin America Hemoglobinopathies Market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 50 Latin America Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 51 Latin America Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 52 Brazil Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 53 Brazil Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 54 Argentina Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 55 Argentina Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 56 Middle East & Africa Hemoglobinopathies Market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 57 Middle East & Africa Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 58 Middle East & Africa Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 59 South Africa Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 60 South Africa Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 61 Saudi Arabia Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 62 Saudi Arabia Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 63 UAE Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 64 UAE Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 65 Kuwait Hemoglobinopathies Market, by disease type, 2021 - 2033 (USD Million/Billion)
  • Table 66 Kuwait Hemoglobinopathies Market, by type, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Hemoglobinopathies Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Hemoglobinopathies Market dynamics
  • Fig. 11 Hemoglobinopathies Market: Porter's five forces analysis
  • Fig. 12 Hemoglobinopathies Market: PESTLE analysis
  • Fig. 13 Disease Type Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 14 Thalassemia Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 15 Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 16 Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 17 Type Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 18 Diagnosis Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 19 Thalassemia Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 20 Blood Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 21 Genetic Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 Prenatal Genetic Testing Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 23 Pre-Implantation Genetic Diagnosis market, 2021 - 2033 (USD Million/Billion)
  • Fig. 24 Hb Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 26 Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 27 Blood Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 28 Genetic Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 29 Prenatal Genetic Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 32 Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 33 Blood Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 34 Genetic Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 35 Prenatal Genetic Test Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 36 Electrophoresis Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 37 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 38 Therapeutics Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 39 Thalassemia Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 40 Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 41 Iron Chelation Therapy Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 42 Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 43 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 Sickle Cell Disease Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 45 Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 46 Hydroxyurea Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 47 Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 49 Other Hemoglobin (Hb) Variants Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 Blood Transfusion Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 51 Hydroxyurea Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 52 Iron Chelation Therapy Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 53 Bone Marrow Transplant Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 54 Others Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 55 Hemoglobinopathies Market revenue, by region
  • Fig. 56 Regional marketplace: Key takeaways
  • Fig. 57 North America Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 58 U.S. country dynamics
  • Fig. 59 U.S. Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 60 Canada country dynamics
  • Fig. 61 Canada Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 62 Mexico country dynamics
  • Fig. 63 Mexico Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 64 Europe Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 65 UK country dynamics
  • Fig. 66 UK Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 67 Germany country dynamics
  • Fig. 68 Germany Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 69 France country dynamics
  • Fig. 70 France Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 71 Italy country dynamics
  • Fig. 72 Italy Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 73 Spain country dynamics
  • Fig. 74 Spain Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 75 Norway country dynamics
  • Fig. 76 Norway Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 77 Sweden country dynamics
  • Fig. 78 Sweden Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 79 Denmark country dynamics
  • Fig. 80 Denmark Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 81 Asia Pacific Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 82 Japan country dynamics
  • Fig. 83 Japan Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 84 China country dynamics
  • Fig. 85 China Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 86 India country dynamics
  • Fig. 87 India Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 88 Australia country dynamics
  • Fig. 89 Australia Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 90 South Korea country dynamics
  • Fig. 91 South Korea Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 92 Thailand country dynamics
  • Fig. 93 Thailand Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 94 Latin America Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 95 Brazil country dynamics
  • Fig. 96 Brazil Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 97 Argentina country dynamics
  • Fig. 98 Argentina Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 99 MEA Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 100 South Africa country dynamics
  • Fig. 101 South Africa Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 102 Saudi Arabia country dynamics
  • Fig. 103 Saudi Arabia Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 104 UAE country dynamics
  • Fig. 105 UAE Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 106 Kuwait country dynamics
  • Fig. 107 Kuwait Hemoglobinopathies Market, 2021 - 2033 (USD Million/Billion)
  • Fig. 108 Company categorization
  • Fig. 109 Company market position analysis
  • Fig. 110 Strategic framework